LPTX Leap Therapeutics Inc.

1.9
-0.1  -5%
Previous Close 2
Open 2.05
Price To Book 8.26
Market Cap 45,970,266
Shares 24,194,877
Volume 742,292
Short Ratio
Av. Daily Volume 797,969
Stock charts supplied by TradingView

NewsSee all news

  1. Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

    CAMBRIDGE, Mass., Jan. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented updated clinical data from its recently completed Phase 1/2 clinical trial of DKN-01 in patients with advanced or

  2. Leap Therapeutics Announces Closing of Previously Announced Equity Financing

    CAMBRIDGE, Mass., Jan. 7, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of its previously

  3. Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

    CAMBRIDGE, Mass. and BEIJING, Jan. 3, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a

  4. Leap Therapeutics Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today reported financial results for the third quarter ended September 30, 2019. "The body of clinical data we presented in the

  5. Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting

    CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data August 6, 2019 noted 50% ORR.
DKN-01 + KEYTRUDA
Esophagogastric adenocarcinoma
Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.
DKN-01
Biliary tract cancer (BTC)
Phase 2 updated data September 20, 2019 at IGCS.
DKN-01 and Paclitaxel
Endometrial Cancer
De-prioritizing further development - November 14, 2019
TRX518
Solid tumors

Latest News

  1. Leap Therapeutics Presents Updated Data at the ASCO 2020 Gastrointestinal Cancers Symposium (ASCO GI) Global Meeting

    CAMBRIDGE, Mass., Jan. 23, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today presented updated clinical data from its recently completed Phase 1/2 clinical trial of DKN-01 in patients with advanced or

  2. Leap Therapeutics Announces Closing of Previously Announced Equity Financing

    CAMBRIDGE, Mass., Jan. 7, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of its previously

  3. Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing

    CAMBRIDGE, Mass. and BEIJING, Jan. 3, 2020 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (NASDAQ:BGNE, HKEX: 06160)), a

  4. Leap Therapeutics Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today reported financial results for the third quarter ended September 30, 2019. "The body of clinical data we presented in the

  5. Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting

    CAMBRIDGE, Mass., Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced an oral and poster presentation of updated clinical data from its ongoing Phase 2 clinical trial of DKN-01, its

  6. Leap Therapeutics to Present at Upcoming Investor Conferences

    CAMBRIDGE, Mass., Sept. 4, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D.,